sertraline mesylate | 264145-31-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: sertraline mesylate
• 英文别名: sertraline mesylate monohydrate；(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate；(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;methanesulfonic acid
• CAS: 264145-31-5
• 化学式: CH₄O₃S*C₁₇H₁₇Cl₂N
• 分子量: 402.342
• InChiKey: GBJNHDSBYFEYPG-XHXSRVRCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.68
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  盐酸舍曲林 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 sertraline mesylate
  参考文献：
  名称：

  Salt Selection and Simultaneous Polymorphism Assessment via High-Throughput Crystallization:  The Case of Sertraline

  摘要：

  High-throughput (HT) crystallization experiments were conducted with sertraline free base in the presence of mono-, di- and triacidic salt formers. Over 3600 crystallization trials were conducted, leading to the identification and characterization of 18 crystalline salt forms. Due to the large number of crystallization conditions for a given salt type, it was possible to gauge the propensity of a given salt form to exhibit polymorphism. Four salt forms were found to exist (in this limited screen) as monomorphic materials. Unlike the HCl salt in the marketed drug product, the HBr salt appears resistant to polymorphism, crystallizing as a single form from over 140 discrete trials. This observation underscores the lack of predictability of polymorphic behavior of pharmaceuticals even when seemingly minor changes to the composition are made. The experiments highlight the importance of coupling salt selection studies with simultaneous polymorph screening to gain a more comprehensive understanding of solid form diversity as part of the form selection process for pharmaceutical development.

  DOI：

  10.1021/op034115+

文献信息

• [EN] SERTRALINE COMPOSITIONS<br/>[FR] COMPOSITIONS DE SERTRALINE
  申请人：TRANSFORM PHARMACEUTICALS INC

  公开号：WO2005000786A1

  公开（公告）日：2005-01-06

  An acid salt of sertraline, wherein the acid is citric acid, fumaric acid, malic acid, maleic acid, malonic acid, phosphoric acid, succinic acid, sulfuric acid, L-tartaric acid, HBr, acetic acid, benzoic acid, benzenesulfonic acid, ethanesulfonic acid, lactic acid, methanesulfonic acid or toluenesulfonic acid. Similarly, a solvate of sertraline HCI, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, acetic acid, ethyl acetate, or propylene glycol.

  一种盐酸舍曲林的酸盐，其中酸为柠檬酸、富马酸、苹果酸、马来酸、丙二酸、磷酸、琥珀酸、硫酸、L-酒石酸、HBr、乙酸、苯甲酸、苯磺酸、乙烷磺酸、乳酸、甲磺酸或甲苯磺酸。同样，一种盐酸舍曲林的溶剂化物，其中溶剂为甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、乙酸、乙酸乙酯或丙二醇。
• SERTRALINE ORAL CONCENTRATE
  申请人：——

  公开号：US20030096868A1

  公开（公告）日：2003-05-22

  The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.

  本发明提供了一种基本上为非水性的、用于口服的液体药物浓缩物，包含舍曲林或其药学上可接受的盐和一个或多个药学上可接受的辅料。本发明还提供了使用该浓缩物组成物制备舍曲林的水溶液的用途。此外，本发明还提供了使用该浓缩物组成物治疗或预防各种疾病或病况的方法。最后，本发明提供了化合物(1S-cis)-4-(3,4-二氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺甲磺酸盐。
• Structural aspects, solid-state properties, and solubility performance of pharmaceutical sertraline-based organic salts
  作者：Luan Farinelli Diniz、Juan Carlos Tenorio、Caue Ribeiro、Paulo de Sousa Carvalho

  DOI：10.1016/j.molstruc.2022.134293

  日期：2023.2

  methanesulfonic acids to improve the thermal stability and solubility of the API. Anion-exchange reaction and solvent crystallizations have been undertaken to prepare salts of the Srt. These crystalline phases have been characterized by single-crystal and powder X-ray diffraction, Fourier transformed infrared spectroscopy, thermal analysis, and solubility measurements. From the single-crystal structures, we have

  盐形成一直是调节活性药物化合物 (API) 的生物制药物理化学性质的传统且成功的策略。在此，我们制备了舍曲林 (Srt) 与草酸、富马酸、马来酸和甲磺酸的四种盐，以提高 API 的热稳定性和溶解度。已进行阴离子交换反应和溶剂结晶以制备 Srt 的盐。这些结晶相已通过单晶和粉末 X 射线衍射、傅里叶变换红外光谱、热分析和溶解度测量进行了表征。从单晶结构中，我们观察到羧酸盐含有阴离子-水簇，引导一维阴离子通道和结构的形成，然后与 Srt +阳离子。无水的甲磺酸盐（SrtH Mes）也具有阳离子和阴离子的交替层状结构。SrtH Mes 是最热稳定的盐（熔点194 ºC），与母体盐酸盐 SrtH Cl 相比，溶解度有所提高。鉴于此配置文件，它代表了新药配方、储存和 API 纯化的替代方案。在这项研究中，我们展示了晶体结构评估及其固态表征的应用，以指导和提供固体形式的选择作为药物开发的候选者。
• Sertraline oral concentrate
  申请人：Pfizer Inc.

  公开号：US20040161434A1

  公开（公告）日：2004-08-19

  The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.

  本发明提供了一种用于口服的基本上非水性的液体浓缩药物组合物，其中含有舍曲林或其药学上可接受的盐以及一种或多种药学上可接受的赋形剂。本发明还提供了使用这种浓缩组合物制备舍曲林水溶液的方法。此外，本发明还提供了一种使用这种浓缩组合物治疗或预防各种疾病或病症的方法。最后，本发明提供了化合物(1S-顺式)-4-(3,4-二氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺甲磺酸盐。
• Sertraline compositions
  申请人：Remenar Julius

  公开号：US20050014829A1

  公开（公告）日：2005-01-20

  An acid salt of sertraline, wherein the acid is citric acid, fumaric acid, malic acid, maleic acid, malonic acid, phosphoric acid, succinic acid, sulfuric acid, L-tartaric acid, HBr, acetic acid, benzoic acid, benzenesulfonic acid, ethanesulfonic acid, lactic acid, methanesulfonic acid or toluenesulfonic acid. Similarly, a solvate of sertraline HCl, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, acetic acid, ethyl acetate, or propylene glycol.

  舍曲林的酸盐，其中酸为柠檬酸、富马酸、苹果酸、马来酸、丙二酸、磷酸、琥珀酸、硫酸、L-酒石酸、HBr、乙酸、苯甲酸、苯磺酸、乙磺酸、乳酸、甲磺酸或甲苯磺酸。同样，盐酸舍曲林的溶液剂，其中溶剂为甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、乙酸、乙酸乙酯或丙二醇。